Home > Insider Trading > Filing (0001225208-17-005446)

Filing Details

Accession Number:: 0001225208-17-005446
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-02 19:34:29
Reporting Period:: 2017-02-28

Filing Date:: 2017-03-02
Accepted Time:: 2017-03-02 19:34:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885725	Boston Scientific Corp	BSX	Surgical & Medical Instruments & Apparatus (3841)	042695240

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1566094	B. Jeffrey Mirviss	300 Boston Scientific Way Marlborough MA 01752-1234	Svp&Pres, Periph Intervent	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-28	24,846	$0.00	110,784	No	4	A	Direct
Common Stock	Acquisiton	2017-02-28	3,721	$0.00	114,505	No	4	M	Direct
Common Stock	Disposition	2017-02-28	10,830	$24.55	103,675	No	4	F	Direct
Common Stock	Disposition	2017-02-28	25,000	$24.67	78,675	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Deferred Stock Units	Disposition	2017-02-28	3,721	$0.00	3,721	$0.00
Common Stock	Deferred Stock Units	Acquisiton	2017-02-28	10,183	$0.00	10,183	$0.00
Common Stock	Performance Share Units	Acquisiton	2017-02-28	13,232	$0.00	13,232	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2017-02-28	32,938	$0.00	32,938	$24.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,722		2018-02-28	No	4	M	Direct
10,183		2022-02-28	No	4	A	Direct
13,232	2018-12-31	2018-12-31	No	4	A	Direct
32,938		2027-02-28	No	4	A	Direct

Footnotes

On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.65 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.